04:00 PM EDT, 06/18/2025 (MT Newswires) -- Incyte ( INCY ) said Wednesday it received US Food and Drug Administration approval for its Monjuvi monoclonal antibody, in combination with rituximab and lenalidomide, to treat adults with follicular lymphoma.

The priority review and FDA approval of the supplemental biologics license application for Monjuvi was based on phase 3 trial data evaluating drug efficacy and safety, according to a statement.

The development marked the second approved indication for Monjuvi in the US, the company said.

Price: 68.41, Change: -0.40, Percent Change: -0.58